Belite Bio

Belite Bio

Pharmaceuticals
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

$6.4B

Market Cap • 10/2/2026

2018

(8 years)

Founded

2022

(4 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

8,2

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

19,6

EPS

—

Market Cap

Market Cap

6,3B

EV

5,8B

EV/Revenue

0

EV/EBITDA

-69

EV/EBIT

-68,9

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-10,7%

Total Yield

-10,7%

Payout

0%

Retained Earnings

-185,3M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

96,7%

Capex/OCF

-0,5%

SBC/OCF

—

% PPE

0,1%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

71,1%

CAGR Net Income 5Y

68,3%

CAGR EPS 5Y

28,9%

CAGR OCF 5Y

52,8%

Leverage

N.D./EBITDA

5,9

Debt/Equity

0%

Current Ratio

50

Quick Ratio

49,9

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium